Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Report: Drug Trial Shows Promise For Treating Postpartum Depression

By Andy Szal | July 14, 2016

The results of a recent small clinical trial could eventually offer hope to women suffering from postpartum depression.

Fortune reports that Massachusetts-based Sage Therapeutics’ experimental drug — called SAGE-547 — led to remission in seven of 10 patients.

A placebo group, by contrast, saw remission in just one of 11 cases, while the drug also reduced depression symptoms at a larger rate than conventional antidepressants.

A previous study eased depression in all four enrolled patients, and the drug also shows promise as a treatment for a rare form of epilepsy.

SAGE-547 is a synthetic version of the hormone allopregnanolone, which is believed to trigger postpartum depression when its levels drop sharply following childbirth. It is given intravenously and would only be given to women whose symptoms prompt hospitalization.

One analyst estimated that 200,000 to 600,000 patients could receive the drug each year.

“The rapid onset of action of this drug observed in the trial is unlike anything else available in the field to date,” Samantha Meltzer-Brody of the University of North Carolina School of Medicine said in a statement. “The data show the potential of the drug to provide relief from the debilitating symptoms of PPD, and to markedly decrease suffering in women who are severely affected.”

The results of the latest study led to a sharp increase in Sage’s stock price, but the Fortune report noted that treatments for depression often falter as clinical trials become larger.

Sage executives hope to conduct a bigger trial to confirm the drug’s dosage before filing with the Food and Drug Administration.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50